Literature DB >> 21377584

Radiofrequency ablation of hepatocellular carcinoma.

Tito Livraghi1.   

Abstract

Radiofrequency ablation (RFA), usually performed under percutaneous ultrasound guidance, is considered the gold standard among minimally invasive therapies. On the strength of some recent randomized trials, its indications include operable patients with small hepatocellular carcinoma and inoperable patients with more advanced disease also in combination with other therapies. RFA has lower complication rates and costs less than surgery. Copyright Â
© 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21377584     DOI: 10.1016/j.soc.2010.11.010

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  5 in total

1.  Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma.

Authors:  Won Hyeok Choe; Young Jun Kim; Hee Sun Park; Sang Woo Park; Jeong Han Kim; So Young Kwon
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Percutaneous radiofrequency ablation for treatment of giant cell tumor of bone guided by real-time US fused with CT.

Authors:  Qiyu Zhao; Lifeng Wang; Fen Chen; Tian-An Jiang
Journal:  J Med Ultrason (2001)       Date:  2013-07-24       Impact factor: 1.314

3.  Radiofrequency ablation of hepatocellular carcinoma sized > 3 and ≤ 5 cm: is ablative margin of more than 1 cm justified?

Authors:  Shan Ke; Xue-Mei Ding; Xiao-Jun Qian; Yi-Ming Zhou; Bao-Xin Cao; Kun Gao; Wen-Bing Sun
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

4.  An in-vitro animal experiment on metal implants' thermal effect on radiofrequency ablation.

Authors:  Zhen-Wen Lin; Hong Chu; Fan He; Lu-Ping Wang; Jian Kong
Journal:  World J Surg Oncol       Date:  2013-06-22       Impact factor: 2.754

5.  Repeated Radiofrequency Ablation Combined With Ablated Lesion Elimination and Transarterial Chemoembolization Improves the Outcome of Solitary Huge Hepatocellular Carcinomas 10 m or Larger.

Authors:  Shan Ke; Jun Gao; Jian Kong; Xue-Mei Ding; Hai-Gang Niu; Zong-Hai Xin; Chun-Min Ning; Shi-Gang Guo; Xiao-Long Li; Long Zhang; Yong-Hong Dong; Wen-Bing Sun
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.